Nicholas Sauter

1.1k total citations
22 papers, 805 citations indexed

About

Nicholas Sauter is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Nicholas Sauter has authored 22 papers receiving a total of 805 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Nicholas Sauter's work include Bone health and treatments (5 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Cancer Diagnosis and Treatment (4 papers). Nicholas Sauter is often cited by papers focused on Bone health and treatments (5 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Cancer Diagnosis and Treatment (4 papers). Nicholas Sauter collaborates with scholars based in United States, Australia and Switzerland. Nicholas Sauter's co-authors include Catherine Van Poznak, Robert G. Maki, Suzanne Chanel, Martin Fleisher, Glenn Heller, Kelly Scheu, Ellin Berman, Ronald M. Lechan, Allan Lipton and Roberto Toni and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Nicholas Sauter

21 papers receiving 780 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nicholas Sauter United States	10	394	225	176	134	133	22	805
Pamela A. Christopherson United States	19	98 0.2×	75 0.3×	1.1k 6.2×	23 0.2×	242 1.8×	54	1.5k
Allan Lipton United States	9	1000 2.5×	45 0.2×	113 0.6×	197 1.5×	214 1.6×	10	1.2k
Niels Borgstein United States	12	75 0.2×	54 0.2×	88 0.5×	16 0.1×	54 0.4×	21	594
F. Yunus United States	8	622 1.6×	16 0.1×	102 0.6×	194 1.4×	319 2.4×	15	979
Manlio Cabria Italy	19	111 0.3×	222 1.0×	48 0.3×	11 0.1×	326 2.5×	36	1.0k
J. Walls United Kingdom	14	310 0.8×	35 0.2×	17 0.1×	111 0.8×	82 0.6×	37	598
Ömer Yerci Türkiye	16	281 0.7×	135 0.6×	30 0.2×	16 0.1×	256 1.9×	76	891
Bijvoet Ol Netherlands	10	515 1.3×	48 0.2×	20 0.1×	266 2.0×	50 0.4×	17	720
Faize Yüksel Türkiye	14	37 0.1×	124 0.6×	103 0.6×	23 0.2×	90 0.7×	31	434
A. Galid Austria	9	519 1.3×	16 0.1×	56 0.3×	113 0.8×	65 0.5×	27	748

Countries citing papers authored by Nicholas Sauter

Since Specialization

Citations

This map shows the geographic impact of Nicholas Sauter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas Sauter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas Sauter more than expected).

Fields of papers citing papers by Nicholas Sauter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas Sauter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas Sauter. The network helps show where Nicholas Sauter may publish in the future.

Co-authorship network of co-authors of Nicholas Sauter

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas Sauter. A scholar is included among the top collaborators of Nicholas Sauter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas Sauter. Nicholas Sauter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Taylor, Matthew H., Sophie Leboulleux, Bhavana Konda, et al.. (2022). Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Medicine. 12(4). 4332–4342. 6 indexed citations

2.

Prince, H. Miles, Larisa J. Geskin, Oleg E. Akilov, et al.. (2022). Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302. Blood. 140(Supplement 1). 6577–6578. 2 indexed citations

3.

Foss, Francine M., Youn H. Kim, H. Miles Prince, et al.. (2022). Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302. Blood. 140(Supplement 1). 1491–1492. 9 indexed citations

4.

Taylor, Matthew H., Sophie Leboulleux, Bhavana Konda, et al.. (2021). 1746P Health-related quality-of-life (HRQoL) analyses from study 211: A phase 2 study in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) treated with 2 starting doses of lenvatinib (LEN). Annals of Oncology. 32. S1205–S1205.

5.

Hamilton, Erika, Allen Lee Cohn, Nicholas Sauter, et al.. (2019). Safety and tolerability of surufatinib in western patients with solid tumours. Annals of Oncology. 30. v569–v570. 1 indexed citations

6.

Wang‐Gillam, Andrea, et al.. (2019). Phase I trial of fruquintinib in patients with advanced solid tumors: Results of the dose escalation phase. Annals of Oncology. 30. v175–v176. 2 indexed citations

7.

Ting, Lillian, Nicholas Sauter, Christelle Darstein, et al.. (2017). Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults. Clinical Drug Investigation. 37(5). 465–472. 30 indexed citations

8.

Hortobágyi, Gabriel N., Catherine Van Poznak, W G Harker, et al.. (2017). Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone. JAMA Oncology. 3(7). 906–906. 104 indexed citations

9.

Pivonello, Rosario, Betül Hatipoğlu, Maria Fleseriu, et al.. (2016). Long-term (19-month) control of urinary free cortisol with osilodrostat in patients with Cushing's disease: results from an extension to the LINC-2 study. Endocrine Abstracts. 1 indexed citations

10.

Fleseriu, Maria, Rosario Pivonello, Jacques Young, et al.. (2015). Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease. Pituitary. 19(2). 138–148. 114 indexed citations

11.

Hortobágyi, Gabriel N., Allan Lipton, Helen K. Chew, et al.. (2014). Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial.. Journal of Clinical Oncology. 32(18_suppl). LBA9500–LBA9500. 21 indexed citations

12.

Weitzman, Richard E., Nicholas Sauter, Erik Fink Eriksen, et al.. (2007). Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006. Critical Reviews in Oncology/Hematology. 62(2). 148–152. 146 indexed citations

13.

Berman, Ellin, Robert G. Maki, Martin Fleisher, et al.. (2006). Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate. New England Journal of Medicine. 354(19). 2006–2013. 217 indexed citations

14.

Poznak, Catherine Van & Nicholas Sauter. (2005). Clinical management of osteoporosis in women with a history of breast carcinoma. Cancer. 104(3). 443–456. 32 indexed citations

15.

Nordquist, Luke T., Nicholas Sauter, Michael J. Morris, et al.. (2004). Hormonal induction followed by rapid hormonal cycling for prostate cancer (PC): the MEN's Cycle. Journal of Clinical Oncology. 22(14_suppl). 4609–4609. 1 indexed citations

16.

Morris, Michael J., William Kevin Kelly, Susan F. Slovin, et al.. (2004). Phase I trial of exogenous testosterone (T) for the treatment of castrate metastatic prostate cancer (PC). Journal of Clinical Oncology. 22(14_suppl). 4560–4560. 1 indexed citations

17.

Kortmansky, Jeremy, Nicholas Sauter, Eileen M. O’Reilly, et al.. (2004). Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracil. Journal of Clinical Oncology. 22(14_suppl). 2140–2140. 4 indexed citations

18.

Kortmansky, Jeremy, Nicholas Sauter, Eileen M. O’Reilly, et al.. (2004). Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracil. Journal of Clinical Oncology. 22(14_suppl). 2140–2140. 2 indexed citations

19.

Sauter, Nicholas, Michael B. Atkins, James W. Mier, & Ronald M. Lechan. (1992). Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after interleukin-2 and interferon-α therapy for metastatic carcinoma: A case report. The American Journal of Medicine. 92(4). 441–444. 36 indexed citations

20.

Sauter, Nicholas, et al.. (1990). Isolated Adrenocorticotropin Deficiency Associated with an Autoantibody to a Corticotroph Antigen That Is not Adrenocorticotropin or Other Proopiomelanocortin-Derived Peptides*. The Journal of Clinical Endocrinology & Metabolism. 70(5). 1391–1397. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact